| Name | Title | Contact Details |
|---|
CODAC Behavioral Health Services of Pima County is a nonprofit 501(c)(3) organization that provides mental health and substance use disorder treatment and prevention programs to children, adults and families in Pima County. It is CODAC’s mission to work collaboratively with individuals, families and organizations to eliminate the harmful effects of substance use disorders, mental illness and abuse on their lives and families. CODAC was founded in 1970 and has evolved into a comprehensive service provider with a full continuum of mental health and substance use disorder treatment programs for youth (ages 12-17), young adults (ages 18-21) and adults (ages 22+) and their families at 10 conveniently located sites. CODAC’s prevention services are community-based and recognized as best-practices for preventing risky behaviors in Pima County youth and families.
Excerpta Medica is a Bridgewater, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Sampling Technologies - STI Smart Technologies is a Lower Sackville, NS-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Health Robotics Canada is a Toronto, ON-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Kymera is a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body’s own natural protein degradation system. Kymera’s proprietary targeted protein degradation platform, called Pegasus, enables us to discover highly selective small molecule protein degraders with activity against disease-causing proteins throughout the body. We believe that our small molecule protein degraders have significant advantages over existing therapies and allow us to address a large portion of the human genome that was previously intractable with traditional modalities. Kymera focuses on biological pathways that have been clinically validated but where key biological nodes/proteins have not been drugged or have been inadequately drugged. To date, we have utilized our Pegasus platform to design novel protein degraders focused in the areas of immunology-inflammation and oncology, and continue to apply our platform’s capabilities to additional therapeutic areas.